爱倍联合低分子肝素治疗不稳定性心绞痛的临床观察  

Clinical effect of Aibei combined with low molecular weight heparin on unstable angina pectoris

作　　者：黄党生[1] 罗北捷[1] 沈东[1] 张许文[1] 张丽伟[1] 亢君[1] 姚凤[1] 

机构地区：[1]解放军第304医院心内科,北京100037

出　　处：《感染．炎症．修复》2002年第2期110-111,共2页Infection Inflammation Repair

摘　　要：目的:观察爱倍联合低分子肝素治疗不稳定性心绞痛的临床疗效。方法:1998年1月～2000年12月我科收治的32例不稳定性心绞痛患者应用爱倍联合低分子肝素治疗。爱倍20～40μg/min 持续静脉泵入,联合低分子肝素40mg 皮下注射,2/d,共7d。观察指标:(1)心绞痛每日发作次数;(2)心电图 ST-T 变化。结果:临床显效24例,占75%;有效8例,占25%;无效0例。心电图完全恢复正常8例,占25%;有改善20例,占62.5%;无变化4例,占12.5%。结论:爱倍联合低分子肝素应用是治疗不稳定性心绞痛的安全、有效方法。Objective:To observe the clinical therapeutic effect of Aibei combined with low molecular weight hep- arin on patients with unstable angina pectoris.Methods;32 patients with unstable angina pectoris received intrave- nously Aeibei 20～40μg/min and low molecular weight heparin subcutaneously (Clexane,40mg twice daily).The course of treatment was one week.Results;Significant effect was achieved in 24 patients (75%),and positive effect in 8 patients(25%).Meanwhile,electrocardiography(ECG) examination revealed normal response in 8 pa- tients(25%),significant improvement in 20 patients (62.5%),and no marked changes in 4 patients(12.5%). Conclusion;Aibei combined with low molecular weight heparin is safe and effective in treating patients with unsta- ble angina pectoris.

关 键 词：爱倍 低分子肝素 不稳定性心绞痛 

分 类 号：R54[医药卫生—心血管疾病]